Submitted by Sara Ribeiro (sara.ribeiro@ucb.br) on 2017-06-05T17:52:22Z
No. of bitstreams: 1
LianaCostaPereiraDissertacao2014.pdf: 1788731 bytes, checksum: aaf1eef40e98ed7a21c08304f7dce33b (MD5) / Approved for entry into archive by Sara Ribeiro (sara.ribeiro@ucb.br) on 2017-06-05T17:54:37Z (GMT) No. of bitstreams: 1
LianaCostaPereiraDissertacao2014.pdf: 1788731 bytes, checksum: aaf1eef40e98ed7a21c08304f7dce33b (MD5) / Made available in DSpace on 2017-06-05T17:54:37Z (GMT). No. of bitstreams: 1
LianaCostaPereiraDissertacao2014.pdf: 1788731 bytes, checksum: aaf1eef40e98ed7a21c08304f7dce33b (MD5)
Previous issue date: 2014-05-29 / Viral infections affect every living organism. Health care programs and vaccines have been developed to control and prevent those infections, but there is still the occurrence of severe diseases and with great social-economic importance, whose only alternative is the treatment with antivirals drugs. Those compounds possess different mechanisms of action and are specific for each virus. Nevertheless, with many viruses resistant strains rise, a growing interest in novel antivirals development or in the improvement of existing drugs have been observed. In the last few years, antimicrobial peptides have shown antiviral activities making them candidates for antiviral drugs. The present study aimed to evaluate the possible antiviral activities of synthetic peptides clavanin MO, LL-37, Cn-AMP1 and variants of the Pa-MAP1 against HSV-1 and the Aichivirus replication. The peptides cytotoxic effects against Vero cells were evaluated by MTT method, whereas the clavanin MO, the Pa-MAP
1.8 and Pa-MAP 18br showed more cytotoxicity, with concentrations higher than 15,4
??M and 12 ??M, respectively. Considering the antivirals assays, it was observed that the peptide Pa-MAP 1 causes 90 % of HSV-1 replication, with a SI higher than 4.8 and a virucidal mechanism of action, but null against the Aichivirus. Futhermore LL- 37 presented 90 % of Aichivirus inhibition, with a SI of 3.4. Others peptides tested showed percentages below 41 %. Future studies are need in order to elucidate which HSV-1 structure does Pa-MAP1 interacts and futher extend to in vivo tests. In summary, this study it is the first one to describe antiviral tests for the treatment of the Aichivirus infection. / As infec????es virais acometem todos os organismos vivos. Para o controle e preven????o dessas infec????es, programas de sa??de p??blica e vacinas t??m sido desenvolvidos, mas ainda h?? a ocorr??ncia de doen??as graves e de grande impacto socioecon??mico cuja ??nica alternativa ?? o tratamento com antivirais. Estes possuem diferentes mecanismos de a????o e s??o espec??ficos para cada tipo viral. Entretanto, o surgimento de variantes resistentes de muitos tipos virais tem levado h?? um crescimento no interesse de desenvolver novos antivirais ou at?? mesmo melhorar os existentes. Nos ??ltimos anos, estudos sobre pept??deos antimicrobianos relatam a atividade antiviral desses compostos, tornando-os candidatos a medicamentos antivirais. O presente estudo teve como objetivo avaliar a poss??vel atividade antiviral dos pept??deos sint??ticos clavanina MO, LL-37, Cn-AMP1 e variantes da Pa-MAP contra o Herpes v??rus humano 1 e Aichiv??rus. O efeito citot??xico dos pept??deos em c??lulas Vero foi avaliado pelo m??todo do MTT, sendo que a clavanina MO, a Pa- MAP 1.8 e Pa-MAP 18br demonstraram maior citotoxicidade em concentra????es maiores que 15,4 ??M, e 12 ??M, respectivamente. Considerando os ensaios antivirais, observou-se que o pept??deo Pa-MAP1 apresentou 90 % de inibi????o da replica????o do HHV-1, com um IS maior que 4,8, sendo que seu mecanismo de a????o foi definido como virucida, por??m contra o Aichiv??rus o PI foi nulo. Al??m disso, LL-37 apresentou 90 % de inibi????o do Aichiv??rus com um IS de 3,4. Os outros pept??deos testados apresentaram percentuais abaixo de 41 % contra ambos os v??rus. Futuros estudos moleculares s??o necess??rios para se determinar com qual estrutura do HHV-1 a Pa-MAP1 interage e para estender os testes para modelos in vivo. Este estudo ?? o primeiro a relatar testes antivirais para o tratamento do Aichiv??rus.
| Identifer | oai:union.ndltd.org:IBICT/oai:bdtd.ucb.br:tede/2139 |
| Date | 29 May 2014 |
| Creators | Vilas Boas, Liana Costa Pereira |
| Contributors | Franco, Oct??vio Luiz, Silva, Paula Andr??ia |
| Publisher | Universidade Cat??lica de Bras??lia, Programa Strictu Sensu em Ci??ncias Gen??micas e Biotecnologia, UCB, Brasil, Escola de Sa??de e Medicina |
| Source Sets | IBICT Brazilian ETDs |
| Language | Portuguese |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, info:eu-repo/semantics/masterThesis |
| Format | application/pdf |
| Source | reponame:Biblioteca Digital de Teses e Dissertações da UCB, instname:Universidade Católica de Brasília, instacron:UCB |
| Rights | info:eu-repo/semantics/openAccess |
| Relation | -2827197273900952156, 500, 500, 600, -6392058866414562720, -5518144268585252051 |
Page generated in 0.0029 seconds